BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Forest Laboratories, Inc. 

909 Third Avenue

New York  New York  10022-4731  U.S.A.
Phone: 212-421-7850 Fax: 212-750-9152


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Explore your potential. Discover the rewards.

At Forest Laboratories, we believe in the power of potential. As one of the fastest growing pharmaceutical companies, we are committed to developing a talented, diverse workforce where individuals can learn, achieve and grow.

Highly skilled scientific teams within our Forest Research Institute enable us to license compounds at virtually any stage—from preclinical development to products that are ready for FDA review—and then complete the development and regulatory work to successfully bring these new products to market. Our products, including Lexapro®, Namenda® and Benicar®, help treat a range of conditions such as depression, anxiety, Alzheimer’s disease and hypertension.

In addition to further developing our established therapeutic franchises (central nervous system, cardiovascular and respiratory), we are expanding the scope of our pipeline to address a wider range of health concerns that affect people every day, such as inflammation and pain. This growth is creating significant new career opportunities, and we invite energetic, skilled professionals to join Forest and contribute to our future success.

Employees are the engine of our rapid growth, and in return we offer the incentives and benefits for a healthy work/life balance.

For career opportunities on Long Island, New Jersey and NYC please visit: www.frx.com

Last Updated: 06-01-2006

 Key Statistics


Email:
Ownership: Public

Web Site: Forest Laboratories, Inc.
Employees: 4,300
Symbol: FRX
 



Industry
Pharmaceutical


Collaborations

Recordati S.p.A  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Sankyo Pharma Inc.  Developer and Forest's partner in the promotion of Benicar, an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

H. Lundbeck A/S  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.

Merz Pharma GmbH & Co. KGaA  Licensing agreement for the development and marketing in the U.S. of memantine for the treatment of Alzheimer's Disease and neuropathic pain. Licensing agreement for neramexane, a patented novel NMDA receptor antagonist that is being investigated for a broad range of possible indications related central nervous system disorders.

Rotta Research Laboratorium S.p.A.  Licensing agreement for the development and marketing in the U.S. of dexloxiglumide for the treatment of patients with constipation-prone irritable bowel syndrome (IBS).





 Company News
Ironwood Pharmaceuticals (IRWD) And Forest Laboratories, Inc. (FRX) Launch New Direct-To-Consumer Awareness Campaign For LINZESS® 4/10/2014 10:16:59 AM    More...
Forest Laboratories, Inc. (FRX) And Almirall Provide Update On The Fixed Dose Combination Of Aclidinium And Formoterol In The U.S. 4/9/2014 9:30:47 AM    More...
Forest Laboratories, Inc. (FRX) Sets Date And Conference Call For Fiscal 2014 Fourth Quarter Earnings 4/1/2014 7:18:22 AM    More...
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Tout Positive Phase 2b Bipolar Depression Data 3/31/2014 6:52:09 AM    More...
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression 3/21/2014 7:05:30 AM    More...
Forest Laboratories, Inc. (FRX) And Adamas Pharmaceuticals Announce Forest’s Submission Of New Drug Application For Memantine Extended Release And Donepezil Fixed-Dose Combination For Alzheimer’s Disease 3/4/2014 10:05:48 AM    More...
Forest Laboratories, Inc. (FRX) Submits A New Drug Application For Nebivolol And Valsartan Combination In Hypertension 2/27/2014 9:51:52 AM    More...
Rumor: AstraZeneca PLC (AZN) Actively Pursued Forest Laboratories, Inc. (FRX) 2/26/2014 7:33:32 AM    More...
Forest Laboratories, Inc. (FRX) Launches STRIDE Patient Support Program For COPD Franchise Products Tudorza® Pressair® And Daliresp® 2/24/2014 9:26:42 AM    More...
Actavis (ACT)' Acquisition Of Forest Laboratories, Inc. (FRX) Will Expand Its Branded Drug Portfolio And Facilitate Long-Term Growth, Says Globaldata Analyst 2/20/2014 9:22:46 AM    More...
12345678910...